1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) Abetalipoproteinaemia (Bassen-Kornzweig syndrome).
1.2 OMIM# of the disease 200100.
1.3 Name of the analysed genes or DNA/chromosome segments MTTP.
OMIM# of the gene(s)
157147.
Mutational spectrum
Over 30 mutations in MTTP have been described, mostly small point mutations (missense, nonsense and splicing) located throughout the gene's 18 exons. [1] [2] [3] [4] [5] [6] The majority of mutations are 'private' to specific families or ethnic communities.
Analytical methods
DNA sequencing of genomic-exonic DNA with at least 20 bp of flanking intronic sequence. In patients where autosomal co-dominant inheritance can not be excluded or MTTP mutation(s) not identified, the APOB gene should be screened; homozygous familial hypobetalipoproteinaemia can give a similar biochemical and clinical phenotype to abetalipoproteinaemia.
Analytical validation
Where a mutation is identified using bi-directional DNA sequencing, the test is repeated from a fresh dilution of DNA for confirmation. When heterozygosity for two mutations is found, testing of the patient's parents is recommended, to confirm that the two mutations are present in trans (that is, on opposite chromosomes).
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) Estimated at o1 in 1 000 000. 1 1.9 If applicable, prevalence in the ethnic group of investigated person Not applicable.
Diagnostic setting

Comment:
Use of genetic testing is essentially limited for confirmatory diagnosis in a subject suspected to be affected, rather than other applications such as predictive testing or pre-natal diagnosis. 
TEST CHARACTERISTICS
Negative clinical predictive value (probability of not developing the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: 100%. Index case in that family had not been tested: Should the constellation of clinical findings be present in an index case, it is possible that they might have homozygous familial hypobetalipoproteinaemia, rather than abetalipoproteinaemia. Homozygous familial hypobetalipoproteinaemia patients receive similar treatment advice as abetalipoproteinaemia patients. Also, there are even rarer conditions called homozygous proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency and familial combined hypolipidemia (due to homozygous mutations in angiopoietin-like protein 3, ANGPTL3) that present with extremely low (but not absent) levels of apoB-containing lipoproteins, but no systemic manifestations. To date, there are only a handful of families in the world reported with these latter two genetic conditions.
CLINICAL UTILITY
3.1 (Differential) diagnosis: The tested person is clinically affected (To be answered if in 1.10 'A' was marked) 3.1.1 Can a diagnosis be made other than through a genetic test? 3.1.2 Describe the burden of alternative diagnostic methods to the patient Abetalipoproteinemia is characterised by the absence of plasma apoBcontaining lipoproteins with marked hypocholesterolaemia, absence of LDL cholesterol and apoB and low triglyceride concentrations. 1, [4] [5] In addition, increased serum transaminases due to hepatic steatosis, acanthocytosis and fat-soluble vitamin deficiency are found. Typically, abetalipoproteinaemia cannot be distinguished from homozygous familial hypobetalipoproteinaemia clinically.
3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged? Not applicable. The impact on prognosis of age at diagnosis, commencement of a low-fat diet and vitamin replacement therapy, and MTTP genotype is variable. Early treament with high oral doses of vitamin E and A can reduce the potential severity of neuropathy and retinopathy. 5, 9 A relative paucity of data makes it difficult to predict clinical outcomes based on MTTP genotype.
Management (please describe)
Patients need to be followed regularly for evaluation of symptoms and complications, and to monitor compliance with therapy.
